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Late relapse of a testicular cancer is an uncommon occurrence. We report a case of late relapse of a testicular tumour combined
with a renal cancer and their successful removal with retroperitoneoscopy. The 36-year-old patient underwent left orchiectomy,
retroperitoneallymphnodedissection,andchemotherapy,becauseofmixedtumorincludingteratomaandembryonalcarcinoma.
18 years after the successful primary therapy elevated serum alpha-fetoprotein level had been conﬁrmed, then MRI and PET-CT
scans demonstrated a 30mm left renal mass and 22mm retroperitoneal lymph node above the bifurcation of the left common
iliac artery. We performed retroperitoneoscopic lymph node dissection and left renal tumour resection in the same session. The
histology revealed embryonal carcinoma for the retroperitoneal lymph node and renal cell carcinoma for the left renal mass. We
can conclude that late followup of patients with testicular tumour is important. Retroperitoneoscopy is feasible approach for the
removal of retroperitoneal lymph node metastasis and resection of renal tumor.
1.Introduction
Most recurrences of testicular cancer after curative therapy
occur in the ﬁrst 2 years [1]. Recurrences are uncommon
after 2 years. Late relapse is deﬁned as tumour recurrence
more than 2 years after complete remission following
primary treatment. Many years after successful treatment,
second primary malignancies can occur [2–4].
Hereinwereportacaseoflaterelapseofanonseminoma-
tousgermcelltumour18yearsafterﬁrstcompleteremission,
combined with a renal cancer and their successful treatment
with retroperitoneoscopy.
2.CaseReport
The 36-year-old patient had a history of left radical inguinal
orchiectomy, open extended bilateral retroperitoneal lymph
node dissection, and chemotherapy because of testicular
cancer before 18 years in another center. The histology
revealed a mixed tumor including teratoma and embryonal
carcinoma in the left testicle and in the paraaortic lymph
nodes. The treatment was successful. During 12 year follow-
up period, there was no recurrence.
18 years after the primary therapy, elevated serum
alpha-fetoprotein level (50, 24ng/mL) was conﬁrmed. By
physical examination, there was no abnormality. MRI scan
demonstrated a 30mm left renal mass (Figure 1)a n d2 2m m
retroperitoneal lymph node above the bifurcation of the left
common iliac artery (Figure 2). PET-CT scan conﬁrmed this
ﬁnding and showed intensive ﬂuorodeoxyglucose uptake in
both lesions. At that time, he was referred to our center. We
performed retroperitoneoscopic lymph node dissection and
left renal tumor resection at the same session. The operation
timewas285minutes,andbloodlosswas150mL.Complica-
tiondidnotoccur.Transfusionorconversiontoopensurgery
was not necessary. The postoperative period was uneventful,
analgesic requirements were moderate, and hospital stay was
3 days. The histology revealed embryonal carcinoma for the
retroperitoneal lymph node and renal cell carcinoma for the
left renal mass. The renal cell carcinoma was independent
of the germ cell tumour. Immunohistochemical staining
showed that tumour cells from the retroperitoneal lymph2 Case Reports in Medicine
Figure 1:Coronalmagneticresonanceimagingscandemonstrating
30mm left renal mass (arrow).
node were negative for vimentin, CD10, and CD30, in
contrast with tumour cells from the renal mass, which were
positive for vimentin and CD10 and negative for CD30. Six
months after the operation, the patient had no recurrence
and serum alpha-fetoprotein level was normal.
3. Discussion
Late relapses of nonseminomatous germ cell tumours are
rare 1–6% of patients have a late relapse [5–8]. Late relapse
may occur at any time, even 32 years after primary treatment
[6, 9].
The most frequent location of late relapse is retroperi-
toneal space. The lungs and the mediastinal lymph nodes
are rarely aﬀected [1, 6, 8, 10]. After retroperitoneal lym-
phadenectomy, relapse in the retroperitoneum is rare, the
most likely site of recurrence being the chest [11].
The optimum treatment for the patient depends on the
primary treatment, histological type of the tumour, and the
location of late relapse. The surgical approach seems to be
the best choice. Survival of patients with late relapse is better,
if they undergo complete surgical resection [1, 6, 10, 12, 13].
Both seminomatous and nonseminomatous germ cell
t u m o u r sc a nr e l a p s ea f t e r2y e a r s .L a t er e l a p s ew i t hn o n -
seminomatous germ cell tumour patients is more frequent
Figure 2:Coronalmagneticresonanceimagingscandemonstrating
22mm retroperitoneal lymph node (arrow).
[7, 10]. Teratoma is the most common type of neoplasm
in late recurrences, followed by yolk sac tumour. Other
types of testicular tumours, including embryonal carcinoma,
seminoma, choriocarcinoma, and nongerm cell malignant
tumours occur rarely [14].
After the introduction of cisplatin-based chemotherapy
forthetreatmentoftesticulargermcelltumours,thesurvival
of patients increase dramatically. Recently, the cure rate is
excellent, even in the advanced stage. Testicular germ cell
cancer occurs predominantly in young adulthood; therefore,
these patients may experience high levels of risk as they reach
older ages [15]. It resulted in increased focus on the serious
treatment-related long term side eﬀects, which can cause
higher mortality rates. Many years after successful treatment,
second primary malignancies can occur as the most serious
late treatment side eﬀect. Testicular cancer survivors are in
greater risk of developing secondary tumours compared to
the general population [2–4]. An increased incidence has
been found following both radiotherapy and chemotherapy
[2].
4. Conclusion
We can conclude that late followup of patients with testicular
cancer is important. Patients treated for testicular cancerCase Reports in Medicine 3
may need annual follow-up evaluations throughout their
life because of the possibility of late relapse and second
primary malignances as well. Retroperitoneoscopy is fea-
sible approach for the removal of retroperitoneal lymph
node metastasis and renal tumor resection even after open
transperitoneal lymph node dissection.
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